Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 24, showing 10 Applications out of 238 total, starting on record 1, ending on 10

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

1.

ECCT/24/02/07   CO-SAM
          An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM)             
Principal Investigator(s)
1. Benson Singa
Site(s) in Kenya
1. Homabay County Referral hospital (Homa Bay county)
2. Migori County Referral Hospital (Migori county)
3. Mbagathi County Referral Hospital (Nairobi City county)
4. Coast General Teaching and Referral Hospital (Mombasa county)
 
03-12-2024 View

2.

ECCT/23/03/05   SKY-06
    A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS   PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER   
Principal Investigator(s)
1. Dr Primus Ochieng
Site(s) in Kenya
1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
11-08-2023 View

3.

ECCT/22/05/02   BREATHER Plus
        A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
25-09-2022 View

4.

ECCT/19/07/01   IMPROVE-2
      chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2).    
Principal Investigator(s)
1. Hellen Cherono Barsosio
2. Simon Kariuki
Site(s) in Kenya
1. Ahero Sub-County Hospital (Kisumu county)
2. Rabuor Sub-County Hospital (Kisumu county)
3. Akala Sub-County Hospital (Siaya county)
 
03-10-2019 View

5.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
21-07-2022 View

6.

21/06/16   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county)
2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county)
3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county)
4. Partners in Health Research and Development, Thika (Kiambu county)
5. KARGENO RESEARCH AND POLICY HUB (Kisumu county)
6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county)
7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county)
9. Aga Khan University Hospital (Nairobi City county)
10. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
02-08-2021 View

7.

ECCT/21/06/03   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the   efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein   Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age   and older   
Principal Investigator(s)
1. PROF.ELIZABETH ANNE BUKUSI
2. MARICIANAH A ONONO
Site(s) in Kenya
1. Kenya Medical Research Institute (KEMRI) Center for Microbiology Research - Research Care and Training Program (KEMRI CMRRCTP) (Kisumu county)
2. KEMRI CCRButere County Hospital Site (Kakamega county)
3. Aga Khan University Hospital (Nairobi City county)
4. Kenya Medical Research Institute CGHR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county)
7. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county)
8. Ganjoni Clinic (Mombasa county)
9. KEMRI-UAMRD-A/K, Kombewa Clinical Research Cente (Kisumu county)
10. KEMRI/Walter Reed Project Research Center (Kericho county)
 
02-08-2021 View

8.

ECCT/21/06/12   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the   efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein   Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age   and older   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. Kenya Medical Research Institute (Kisumu county)
4. Ganjoni Clinic (Mombasa county)
5. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county)
6. Kenya Medical Research Institute (Nairobi City county)
7. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Bung\'oma county)
 
16-08-2021 View

9.

ECCT/25/04/01   PHASE 2/3 OF SII-TCV(B)
    A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS   
Principal Investigator(s)
1. WALTER OTIENO
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
07-10-2025 View

10.

ECCT/22/06/02   Mitapivat - AG348-C-020
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.   
Principal Investigator(s)
1. Lucas Otieno Tina
2. Bernhards Ragama Ogutu
3. Prof Jessie N Githanga
4. Videlis N Nduba
5. Janet N/A Oyieko
6. Allan Godfrey Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Strathmore University Medical Centre (Nairobi City county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Kombewa Clinical Research Centre (Kisumu county)
 
06-09-2022 View